Regenxbio Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
Hey, everyone. Good afternoon and welcome to Day 3 of the BofA Health Care Conference. Thanks for joining the session with REGENXBIO. My name is Alec Stranahan, I'm an analyst on the U.S. bio pharma team here at BofA. And I'm pleased to be joined today by Ken Mills, President and CEO of REGENXBIO.
And I believe Ken is going to run through some initial comments to start, and then we'll jump into some Q&A. So with that, Ken, over to you.
Thanks, Alec. Appreciate the invitation as always from you and the BofA team and the good work to put this conference on in the virtual format.
Just an introduction to REGENXBIO, for those of you that know us and don't know us, we've been a leader in the gene therapy field for more than a decade, focused on development of what we think are highly curative potential AAV gene therapies. Inside the company, we're advancing a broad pipeline programs with multiple ongoing
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
